Harvard Apparatus Regenerative Technology HRGN

Harvard Apparatus Regenerative Technology is a clinical-stage biotechnology company focused on developing regenerative medicine treatments for disorders of the gastrointestinal system and other organs resulting from cancer, trauma, or birth defects. The company’s core technology uses a patient’s own mesenchymal stem cells seeded on a temporary polyurethane scaffold to regenerate damaged organs, eliminating the need for donor transplants or permanent artificial implants. Its lead product candidate, the Cellspan™ Esophageal Implant, is designed to regenerate esophageal tissue following resection due to cancer, injury, or congenital conditions.

The company generates revenue primarily through the anticipated future commercialization of its regenerative medicine products, particularly the Cellspan™ Esophageal Implant, which it expects to sell to hospitals and healthcare providers for implantation procedures. Revenue is also generated from its Consumer Health Products subsidiary, which sells dietary supplements and other personal healthcare products globally through eCommerce channels, initially targeting consumers in Asia. The subsidiary operates under an exclusive distribution agreement with Health Regen, Inc., granting global distribution rights for its consumer health products from November 2024 through December 2030.

The company operates through the following segments: Regenerative Biotech and Consumer Health Products.

• Regenerative Biotech: This segment focuses on the development and clinical advancement of organ-regeneration technologies, with the Cellspan™ Esophageal Implant as its lead product candidate for treating esophageal disease, injury, and birth defects. The technology involves harvesting a patient’s adipose-derived mesenchymal stem cells, seeding them onto a tubular polyurethane scaffold in a bioreactor, and implanting the construct to regenerate esophageal tissue, which is later removed endoscopically after tissue integration. The segment includes preclinical and clinical development activities, regulatory strategy, manufacturing of scaffolds and bioreactors in Holliston, Massachusetts, and collaborations with institutions such as the Mayo Clinic, Connecticut Children’s Medical Center, Yale University, and the McGowan Institute for Regenerative Medicine at the University of Pittsburgh.
• Consumer Health Products: This segment, operated through the company’s Hong Kong subsidiary Harvard Apparatus Regenerative Technology Limited, focuses on the sale of consumer health products, including dietary supplements marketed under the longevity products line. These products are commercially available to the general public via eCommerce platforms, with initial market focus on consumers in Asia. The segment functions under an exclusive distribution agreement with Health Regen, Inc., which holds global distribution rights for all consumer health products from November 1, 2024, to December 31, 2030.

Harvard Apparatus Regenerative Technology holds a pioneering position in the regenerative medicine field, particularly in esophageal tissue regeneration, with no direct competitors currently offering a comparable cell-seeded, retrievable scaffold system for autologous organ regeneration. The company’s competitive advantages include its proprietary technology platform, thirteen issued U. S. patents covering the bioreactor, scaffold, and surgical procedure, two FDA Orphan Drug Designations conferring seven years of U. S. market exclusivity post-approval, and an EMA Orphan Drug Designation providing ten years of exclusivity in Europe. Its first-mover status in human esophageal regeneration, demonstrated by the world’s first successful case in 2017, further strengthens its intellectual property and clinical differentiation.

The company serves patients requiring esophageal reconstruction due to cancer, trauma, or birth defects, with clinical trial sites activated at the Mayo Clinic, the University of Michigan Medical Center, and the University of Southern California in Los Angeles. Its Consumer Health Products segment serves individual consumers in Asia and globally through online sales of dietary supplements and wellness products. No specific customer names are disclosed in the filing for either segment.